Reata Pharmaceuticals Inc
NASDAQ:RETA
Net Margin
Reata Pharmaceuticals Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | US |
Market Cap | 6.5B USD |
Net Margin |
-373%
|
Country | JP |
Market Cap | 776 550.9T JPY |
Net Margin |
-79%
|
Country | US |
Market Cap | 763.3B USD |
Net Margin |
17%
|
Country | DK |
Market Cap | 4.1T DKK |
Net Margin |
37%
|
Country | UK |
Market Cap | 440.4B GBP |
Net Margin |
-4%
|
Country | US |
Market Cap | 363.3B USD |
Net Margin |
45%
|
Country | US |
Market Cap | 330.5B USD |
Net Margin |
4%
|
Country | UK |
Market Cap | 191.7B GBP |
Net Margin |
13%
|
Country | CH |
Market Cap | 188B CHF |
Net Margin |
20%
|
Country | CH |
Market Cap | 183.5B CHF |
Net Margin |
30%
|
Country | US |
Market Cap | 161.7B USD |
Net Margin |
-1%
|
Profitability Report
View the profitability report to see the full profitability analysis for Reata Pharmaceuticals Inc.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Reata Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of -373.2%.